Original Data vs Copies in Clinical Trials: What Regulators Expect

Understanding the ALCOA Principle of “Original” Data

In the ALCOA framework, “Original” refers to the first capture of information. Whether handwritten on a paper log or directly entered into an Electronic Data Capture (EDC) system, this initial recording becomes the authoritative source. Maintaining the originality of data ensures its credibility and prevents tampering, duplication, or loss of context.

According to the FDA guidance on Electronic Source Data in Clinical Investigations, the original data is “the first recording of information, whether recorded on paper or electronically.” The EMA also supports the use of certified copies but emphasizes traceability, validation, and documentation control.

For example, a vital sign recorded at the bedside in a subject’s paper chart is considered original. If later transcribed into a CRF, the CRF is a copy—and must be verified against the source.

Defining Certified Copies vs Duplicates

Regulatory authorities differentiate between legitimate certified copies and uncontrolled duplicates. A certified copy is a verified reproduction of an original record that maintains the content and meaning of the original, including metadata like date, time, and identity of the person recording the data.

By contrast, unverified duplicates (e.g., uncontrolled scans or printouts) pose a risk of data divergence or loss of context. Sponsors and sites must ensure that any transformation of original data—such as scanning, transcribing, or converting—is done according to documented procedures.

Here is a simple comparison table:

For guidance on creating certified copies, refer to the document control SOP templates available at PharmaSOP.in.

Regulatory Case Studies and Inspection Findings

In a 2021 FDA inspection of a metabolic study site, multiple entries in the EDC were found without available source records. The site relied on nurses’ verbal confirmations and backfilled CRFs—triggering a 483 citing “absence of original source documentation.”

Similarly, an EMA inspection revealed that scans of ECG strips lacked timestamps and operator initials, failing to meet criteria for certified copies. These were deemed non-compliant and removed from the primary dataset.

Such cases emphasize that unless a scanned or transcribed document is verified and traceable, it cannot replace the original.

More inspection summaries can be reviewed at ClinicalStudies.in.

Best Practices for Managing Original Data in Clinical Trials

Managing original data effectively requires a combination of procedural controls, system validation, and trained personnel. Whether using paper, electronic, or hybrid documentation systems, the following practices are essential:

• Define the “source” in the protocol or source data agreement (SDA): Clearly identify where the original data will be captured for each data point.
• Ensure controlled access: Only authorized individuals should have access to modify or archive original records.
• Implement version control: If documents are scanned or copied, ensure each version is traceable with a documented audit trail.
• Certify electronic copies: Use validated scanners and SOP-driven certification workflows to ensure fidelity of reproduction.
• Store originals securely: Both paper and electronic records must be stored in validated, GCP-compliant environments.

For example, a CRO managing a rare disease trial implemented a centralized scanning system for site-submitted source documents. Each scanned file included metadata (date, operator ID, resolution) and was certified via an automated PDF tool. The sponsor received positive remarks during a joint EMA-FDA inspection.

For tools and validated procedures, see resources at pharmaValidation.in.

How to Document and Justify the Use of Copies

If the original record is unavailable due to operational necessity (e.g., patient diaries lost or destroyed), the use of a copy may be acceptable—but only if documented properly.

Key steps:

• Deviation or note-to-file: Include a rationale explaining why the original was unavailable and how the copy was obtained.
• PI sign-off: The Principal Investigator should confirm the authenticity of the copy.
• Label the document: Mark as “Certified Copy” with initials, date, and version number.
• Retain audit trail: Include details of who certified the copy and under what SOP.

A documented process prevents regulatory challenges and reinforces data credibility. Sponsors should train sites during SIVs on the difference between working copies, certified copies, and originals.

Templates for documentation can be downloaded from PharmaGMP.in.

Conclusion: Protecting the Integrity of Original Data

In the evolving landscape of digital and hybrid trials, protecting the originality of clinical data is more critical than ever. Whether in paper logs, bedside instruments, or EHRs, the first record of data serves as the foundation for evidence-based clinical outcomes.

Sponsors and sites must implement robust SOPs, validated systems, and staff training to differentiate and preserve original data, and ensure that any copy used meets the strict definition of a “certified copy.”

Regulatory bodies expect traceability, consistency, and clear documentation of the origin of data used in clinical submissions. Failing to meet these expectations can jeopardize not just a trial, but an entire development program.

For more on source data protection and certified copy validation, consult WHO’s documentation policies at who.int or explore training modules at PharmaRegulatory.in.